NCT01591356View on ClinicalTrials.gov

EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Advanced Malignant Solid Neoplasm
Interventions
DRUG

EphA2-targeting DOPC-encapsulated siRNA

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Gateway for Cancer Research

OTHER

collaborator

Institutional Funding for Federally Supported Clinical Trials (IFSCT)

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER